9Probiotics in functional bowel disorders
Section snippets
Functional bowel disorders
Functional bowel disorders (FBDs) are a group of functional gastrointestinal (GI) disorders characterized by symptoms attributed to the middle and lower GI tract not explained by unified structural and/or biochemical abnormalities [1], [2]. FBDs include IBS, functional bloating, functional constipation, functional diarrhea, and unspecified functional bowel disorder [1]. In the absence of identifiable unified etiopathophysiology the diagnosis of FBDs relies on clinical presentation, use of
The role of the intestinal microbiota in functional bowel disorders
The intestinal microbiota, the complex community of microorganisms residing in the GI tract is believed to contain greater than 1,000 different bacterial species that can reach viable numbers of 1014 bacteria per gram of luminal content. The highest density of the human intestinal microbiota is in the colon and is dominated by two main bacterial genera Firmicutes (64%) and Bacteroidetes (23%) followed by Proteobacteria (8%) and Actinobacteria (3%) [9], [10]. The intestinal microbiota plays an
The scientific basis for the use of probiotics in functional bowel disorders
The probiotic concept suggests that supplementation of the intestinal microbiota with the right types and numbers of live microorganisms can improve the microbiota characteristics and promote health [32], [33], [34]. In theory, certain probiotics can help restore the proper balance of the intestinal microbiota, lead to better digestive and intestinal function, and possibly improve GI symptoms.
Several randomized control trials (RCT's) comparing the effects of probiotics versus placebo in
Conclusions and clinical implications of current data
Emerging data from microbiome research in patients with FBDs suggests a role for the intestinal microbiota in IBS and possibly in other FBDs including abdominal bloating and constipation. This together with the growing interest of the general public in healthy food, direct-to-consumer advertisement and clinical data on beneficial effects of probiotics in various GI conditions such as infectious diarrhea, antibiotic associated diarrhea and some forms of inflammatory bowel disorders, has led to
Conflict of interest statement
Keren Hod: None.
Yehuda Ringel: Consultant, advisory board and research grants with Nestle, Procter & Gamble, Salix Pharmaceuticals, Danisco, Prometheus Therapeutics and Diagnostics.
References (80)
- et al.
Functional bowel disorders
Gastroenterology
(2006 Apr) - et al.
The epidemiology of irritable bowel syndrome in North America: a systematic review
Am J Gastroenterol
(2002 Aug) - et al.
The genetics of irritable bowel syndrome
Clin Gastroenterol Hepatol
(2005 Nov) - et al.
Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications
Cell Host Microbe
(2012 Nov 15) - et al.
Communication between gastrointestinal bacteria and the nervous system
Curr Opin Pharmacol
(2012 Dec) - et al.
Antibiotics increase functional abdominal symptoms
Am J Gastroenterol
(2002 Jan) - et al.
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2009 Dec) - et al.
Alterations in the intestinal microbiota and functional bowel symptoms
Gastrointest Endosc Clin N Am
(2009 Jan) - et al.
Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome
Gastroenterology
(2011 Nov) - et al.
A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome
Dig Liver Dis
(2015 Feb)
Effect of synbiotic in constipated adult women – a randomized, double-blind, placebo-controlled study of clinical response
Clin Nutr
The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials
Am J Clin Nutr
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles
Gastroenterology
Irritable bowel syndrome. Netter's textbook of internal medicine
Impact of functional gastrointestinal disorders on survival in the community
Am J Gastroenterol
Burden of gastrointestinal, liver, and pancreatic diseases in the United States
Gastroenterology
Peripheral mechanisms in irritable bowel syndrome
N Engl J Med
Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms
J Physiol
Metagenomic analysis of the human distal gut microbiome
Science
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
Nat Rev Neurosci
Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders
Front Cell Neurosci
Postinfectious irritable bowel syndrome–a meta-analysis
Am J Gastroenterol
Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter
Neurogastroenterol Motil
Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS
Gut
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Gut
Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?
Am J Gastroenterol
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Gut
Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome
Am J Physiol Gastrointest Liver Physiol
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
Neurogastroenterol Motil
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Gut
Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome
Gut
The intestinal microbiota and irritable bowel syndrome
J Clin Gastroenterol
Mechanisms and efficacy of dietary FODMAP restriction in IBS
Nat Rev Gastroenterol Hepatol
Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets
Aliment Pharmacol Ther
Recommendations for probiotic use-2015 update: proceedings and consensus opinion
J Clin Gastroenterol
Microbiota restoration: natural and supplemented recovery of human microbial communities
Nat Rev Microbiol
Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases
Front Microbiol
Probiotics: healthy bugs and nourishing elements of diet
J Int Soc Prev Community Dent
The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial
J Clin Gastroenterol
A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome
Int J Colorectal Dis
Cited by (26)
Probiotic-containing edible films and coatings of biopolymers
2020, Biopolymer Membranes and Films: Health, Food, Environment, and Energy ApplicationsProbiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome – What is the current evidence?
2019, Complementary Therapies in MedicineCitation Excerpt :The health-promoting benefits of probiotics include preventing the colonization or curbing the growth of pathogenic bacteria, enhancing epithelial barrier functions, stimulating the host immune response, and modulating the inflammatory gene expression in the gut.12,13 The potentials for probiotics to modulate gut microbiome and thus correct the dysbiosis support its use in IBS.14–16 We found a total of 11 systematic reviews and/or meta-analyses 17,18,27,17–27 published over the last 5 years.
Soybean protein-based microparticles for oral delivery of probiotics with improved stability during storage and gut resistance
2018, Food ChemistryCitation Excerpt :However, over 70% of the fecal microbiota is remarkably stable (Faith et al., 2013). An imbalance in the colonic microbiota may contribute to the development of different disorders including gastrointestinal tract infections, irritable syndromes, allergies, heart diseases and colon cancer (Hod & Ringel, 2016; Zoumpopoulou, Pot, Tsakalidou, & Papadimitriou, 2017). Nowadays, it is still unclear if intestinal bowel diseases-associated dysbiosis is causative, contributory, or consequential to the disease.
Single-particle analysis of circulating bacterial extracellular vesicles reveals their biogenesis, changes in blood and links to intestinal barrier
2023, Journal of Extracellular Vesicles